Drugs A-Z Is my price fair? Price changes Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme

Brand-name drug

Enbrel price, strengths & recalls

Brand of etanercept (generic)

Pharmacies pay $8,326.72 for 4 mL of Enbrel 50 mg/mL, 1 mL cartridge this week, and from $4,167.55 to $8,334.50 across its 4 priced strengths and forms. It has 1 recall on record, none ongoing. Its official label last changed on March 9, 2026.

Medicare price 2026Brand
Pharmacies pay$8,326.72for 4 mL of 50 mg/mL, 1 mL cartridgeNo change in 4 weeks
Fair cash price
$9,586.23
Strengths
4
Makers
1
Updated
Nov 11

Enbrel price by strength

What pharmacies pay for each strength and form this week (Nov 11, 2026), for the usual package. Choose one for its fair price, 52-week chart and makers.

Strength and formPer unitPharmacies pay4 weeks52 weeks
50 mg/mL, 1 mL auto-injector Brand$2,083.62$8,334.50 / 4 mLNo change+5.0%
50 mg/mL, 1 mL cartridge Brand$2,081.68$8,326.72 / 4 mLNo change+5.0%
50 mg/mL, 0.5 mL prefilled syringe Brand$2,083.78$4,167.55 / 2 mLNo change+5.4%
50 mg/mL, 1 mL prefilled syringe Brand$2,080.97$8,323.88 / 4 mLNo change+5.0%

Enbrel vs generic etanercept

There is no generic version of Enbrel on the market yet.

GenericEtanercept prices

Medicare negotiated price

$7,106.00$2,355.00-67%

Medicare negotiated a maximum fair price of $2,355.00 for a 30-day supply of Enbrel, against a 2023 list price of $7,106.00. It has applied since January 1, 2026.

What this means for patients

  • The negotiated price is what Medicare Part D plans pay for the drug - not your price at the counter.
  • What you pay depends on your plan's copay or coinsurance and where you are in the year. Coinsurance (a percentage) falls with the price; a flat copay may not change at all.
  • Out-of-pocket costs for Part D drugs are capped each year ($2,100 in 2026), whatever the drug.
  • If you don't have Medicare, the negotiated price doesn't apply to you - check the fair cash price above instead.
Every Medicare negotiated price

Supply status: shortages & recalls

No shortage reportedChecked Nov 15, 2026
No ongoing recalls1 recall on record, latest May 16, 2018

Recalls

A recall names specific lots. Check the lot number on your package against the recall before you worry - and don't stop a medicine without asking your pharmacist. What to do if your medication is recalled.

What did you pay for enbrel? Help the next person.

Every price shared helps the next person know what's fair - and shows which pharmacies charge the least. Anonymous, 30 seconds.

How were you treated? optional

Free, anonymous, no sign-up. Please don't include personal or health details. Community rules.

Official label & what changed

Last changedMarch 9, 2026
Version218 of 44
EffectiveMay 11, 2026
Read the label

These highlights do not include all the information needed to use ENBREL safely and effectively. See full prescribing information for ENBREL. ENBREL® (etanercept) injection, for subcutaneous use ENBREL® (etanercept) for injection, for subcutaneous use Initial U.S. Approval: 1998

This drug has a boxed warning

WARNING: SERIOUS INFECTIONS and MALIGNANCIES

WARNING: SERIOUS INFECTIONS and MALIGNANCIES

See full prescribing information for complete boxed warning.

SERIOUS INFECTIONS

Increased risk of serious infections leading to hospitalization or death, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to other opportunistic pathogens. (5.1)

Enbrel should be discontinued if a patient develops a serious infection or sepsis during treatment. (5.1)

Perform test for latent TB; if positive, start treatment for TB prior to starting Enbrel. (5.1)

Monitor all patients for active TB during treatment, even if initial latent TB test is negative. (5.1)

MALIGNANCIES

Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF-blockers, including Enbrel. (5.3)

SERIOUS INFECTIONS

Patients treated with Enbrel are at increased risk for developing serious infections that may lead to hospitalization or death [see Warnings and Precautions (5.1) and Adverse Reactions (6)]. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids.

Enbrel should be discontinued if a patient develops a serious infection or sepsis.

Reported infections include:

Active tuberculosis, including reactivation of latent tuberculosis. Patients with tuberculosis have frequently presented with disseminated or extrapulmonary disease. Test patients for latent tuberculosis before Enbrel use and during therapy. Initiate treatment for latent infection prior to Enbrel use.

Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Consider empiric anti-fungal therapy in patients at risk for invasive fungal infections who develop severe systemic illness.

Bacterial, viral, and other infections due to opportunistic pathogens, including Legionella and Listeria.

The risks and benefits of treatment with Enbrel should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection.

Monitor patients closely for the development of signs and symptoms of infection during and after treatment with Enbrel, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy.

MALIGNANCIES

Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF-blockers, including Enbrel.

Recent major changes (as listed on the label)

Indications and Usage, Juvenile Psoriatic Arthritis (1.6) | 10/2023 |

Dosage and Administration, Pediatric Patients (2.4) | 10/2023 |

We check this label every day. When it changes, the sections that changed appear here, old text beside new.

We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.

Approval, patents & generics

Application
BLA103795 · Immunex
First approved
November 2, 1998 (28 years ago)
Latest approved change
October 14, 2026
Approved label
PDF, Feb 6, 2026
Generic makers
None on the market

Enbrel questions

How much does enbrel cost without insurance?

Pharmacies pay about $8,326.72 for 4 mL of enbrel 50 mg/mL, 1 mL cartridge ($2,081.68 per mL). A fair cash price - that cost plus a 15% margin and a typical dispensing fee - is about $9,586.23. If you're quoted much more, check your quote and ask for the pharmacy's cash price.

Is there a generic for Enbrel?

Yes: etanercept. Compare etanercept prices.

Is enbrel in shortage?

No shortage is reported for enbrel right now. We check the national shortage list every day.

Has enbrel been recalled?

1 recall on record, none ongoing. Recalls name specific lots - check yours.

When did the enbrel label last change?

The official label was last updated on March 9, 2026 (version 218). See what changed.

Does Medicare have a negotiated price for Enbrel?

Yes: $2,355.00 for a 30-day supply of Enbrel, from January 1, 2026. What you pay still depends on your plan.

Talk about enbrel

Be kind and stay on topic. No personal health details, links or selling. This is not medical advice.

No comments yet. Questions, tips, what worked for you - start the conversation.

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.